Guardian Pharmacy Services Stock Analysis
| GRDN Stock | 33.46 0.31 0.94% |
At this time, Guardian Pharmacy's Long Term Debt To Capitalization is very stable compared to the past year. As of the 16th of February 2026, Debt Ratio is likely to grow to 0.26, while Short and Long Term Debt is likely to drop about 7.8 M. With a high degree of financial leverage come high-interest payments, which usually reduce Guardian Pharmacy's Earnings Per Share (EPS).
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.13 | Current Value 0.26 | Quarterly Volatility 0.04386627 |
Guardian Pharmacy Services is fairly valued with Real Value of 33.56 and Target Price of 35.0. The main objective of Guardian Pharmacy stock analysis is to determine its intrinsic value, which is an estimate of what Guardian Pharmacy Services is worth, separate from its market price. There are two main types of Guardian Pharmacy's stock analysis: fundamental analysis and technical analysis.
The Guardian Pharmacy stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Guardian Pharmacy is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Guardian Stock trading window is adjusted to America/New York timezone.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Guardian Pharmacy Services. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates. Guardian Stock Analysis Notes
About 38.0% of the company shares are held by company insiders. The company had not issued any dividends in recent years. To learn more about Guardian Pharmacy Services call Fred Burke at 404 810 0089 or check out https://guardianpharmacy.com.Guardian Pharmacy Quarterly Total Revenue |
|
Guardian Pharmacy Investment Alerts
| The company reported the previous year's revenue of 1.23 B. Net Loss for the year was (71.03 M) with profit before overhead, payroll, taxes, and interest of 274.32 M. | |
| Guardian Pharmacy has a poor financial position based on the latest SEC disclosures | |
| About 59.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: New York State Common Retirement Fund Sells 347,524 Shares of Guardian Pharmacy Services, Inc. GRDN - MarketBeat |
Guardian Largest EPS Surprises
Earnings surprises can significantly impact Guardian Pharmacy's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-04-01 | 2025-03-31 | 0.22 | 0.19 | -0.03 | 13 | ||
2024-11-12 | 2024-09-30 | 0.19 | -2.0 | -2.19 | 1152 |
Guardian Pharmacy Environmental, Social, and Governance (ESG) Scores
Guardian Pharmacy's ESG score is a quantitative measure that evaluates Guardian Pharmacy's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Guardian Pharmacy's operations that may have significant financial implications and affect Guardian Pharmacy's stock price as well as guide investors towards more socially responsible investments.
Guardian Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.12 B.Guardian Profitablity
The company has Profit Margin (PM) of 0.03 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.04 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.04.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.40) | |
| Return On Capital Employed | (0.41) | (0.39) | |
| Return On Assets | (0.31) | (0.30) | |
| Return On Equity | (0.70) | (0.67) |
Management Efficiency
Guardian Pharmacy has return on total asset (ROA) of 0.1055 % which means that it generated a profit of $0.1055 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.24 %, meaning that it created $0.24 on every $100 dollars invested by stockholders. Guardian Pharmacy's management efficiency ratios could be used to measure how well Guardian Pharmacy manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of February 2026, Return On Tangible Assets is likely to grow to -0.4. In addition to that, Return On Capital Employed is likely to grow to -0.39. At this time, Guardian Pharmacy's Non Currrent Assets Other are very stable compared to the past year. As of the 16th of February 2026, Intangible Assets is likely to grow to about 13.9 M, while Total Assets are likely to drop about 264 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.18 | 2.29 | |
| Tangible Book Value Per Share | 0.95 | 1.00 | |
| Enterprise Value Over EBITDA | (34.13) | (32.43) | |
| Price Book Value Ratio | 10.13 | 9.62 | |
| Enterprise Value Multiple | (34.13) | (32.43) | |
| Price Fair Value | 10.13 | 9.62 | |
| Enterprise Value | 1.2 B | 1 B |
Management at Guardian Pharmacy focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Technical Drivers
As of the 16th of February 2026, Guardian Pharmacy retains the market risk adjusted performance of 0.1473, and Risk Adjusted Performance of 0.0709. Guardian Pharmacy technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Guardian Pharmacy Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Guardian Pharmacy middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Guardian Pharmacy. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Guardian Pharmacy Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Guardian Pharmacy insiders, such as employees or executives, is commonly permitted as long as it does not rely on Guardian Pharmacy's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Guardian Pharmacy insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
David Morris few days ago Acquisition by David Morris of 50000 shares of Guardian Pharmacy at 34.59 subject to Rule 16b-3 | ||
Forbes Kendall over two months ago Disposition of 21500 shares by Forbes Kendall of Guardian Pharmacy subject to Rule 16b-3 | ||
Bindley Capital Partners I, Llc over six months ago Disposition of 651454 shares by Bindley Capital Partners I, Llc of Guardian Pharmacy at 20.16 subject to Rule 16b-3 | ||
Bindley Capital Partners I, Llc over six months ago Disposition of 3508905 shares by Bindley Capital Partners I, Llc of Guardian Pharmacy at 20.16 subject to Rule 16b-3 | ||
Patchett Mary Sue over six months ago Acquisition by Patchett Mary Sue of 01 shares of Guardian Pharmacy subject to Rule 16b-3 | ||
Lewis Randall J over six months ago Acquisition by Lewis Randall J of 01 shares of Guardian Pharmacy subject to Rule 16b-3 | ||
Salentine Thomas J Jr over six months ago Acquisition by Salentine Thomas J Jr of 6100176 shares of Guardian Pharmacy subject to Rule 16b-3 |
Guardian Pharmacy Outstanding Bonds
Guardian Pharmacy issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Guardian Pharmacy uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Guardian bonds can be classified according to their maturity, which is the date when Guardian Pharmacy Services has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Guardian Pharmacy Predictive Daily Indicators
Guardian Pharmacy intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Guardian Pharmacy stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Guardian Pharmacy Corporate Filings
13A | 13th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
13A | 10th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
13A | 21st of January 2026 An amended filing to the original Schedule 13G | ViewVerify |
8K | 13th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 8th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 5th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2025 An amended filing to the original Schedule 13G | ViewVerify |
13A | 12th of November 2025 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Guardian Pharmacy Forecast Models
Guardian Pharmacy's time-series forecasting models are one of many Guardian Pharmacy's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Guardian Pharmacy's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Guardian Pharmacy Bond Ratings
Guardian Pharmacy Services financial ratings play a critical role in determining how much Guardian Pharmacy have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Guardian Pharmacy's borrowing costs.| Piotroski F Score | 4 | Poor | View |
| Beneish M Score | (5.55) | Unlikely Manipulator | View |
Guardian Pharmacy Total Assets Over Time
Guardian Pharmacy Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Guardian Pharmacy uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Guardian Pharmacy Debt Ratio | 26.0 |
Guardian Pharmacy Corporate Bonds Issued
Guardian Short Long Term Debt Total
Short Long Term Debt Total |
|
About Guardian Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Guardian Pharmacy prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Guardian shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Guardian Pharmacy. By using and applying Guardian Stock analysis, traders can create a robust methodology for identifying Guardian entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.06) | (0.06) | |
| Operating Profit Margin | (0.06) | (0.06) | |
| Net Loss | (0.08) | (0.08) | |
| Gross Profit Margin | 0.23 | 0.22 |
Current Guardian Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Guardian analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Guardian analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 35.0 | Strong Buy | 3 | Odds |
Most Guardian analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Guardian stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Guardian Pharmacy, talking to its executives and customers, or listening to Guardian conference calls.
Guardian Stock Analysis Indicators
Guardian Pharmacy Services stock analysis indicators help investors evaluate how Guardian Pharmacy stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Guardian Pharmacy shares will generate the highest return on investment. By understating and applying Guardian Pharmacy stock analysis, traders can identify Guardian Pharmacy position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 752 K | |
| Common Stock Shares Outstanding | 62 M | |
| Total Stockholder Equity | 142.7 M | |
| Total Cashflows From Investing Activities | -30.4 M | |
| Tax Provision | 4.6 M | |
| Property Plant And Equipment Net | 79 M | |
| Cash And Short Term Investments | 4.7 M | |
| Cash | 4.7 M | |
| Accounts Payable | 102.4 M | |
| Net Debt | 32.7 M | |
| 50 Day M A | 30.8482 | |
| Total Current Liabilities | 144.1 M | |
| Other Operating Expenses | 1.3 B | |
| Non Current Assets Total | 168.8 M | |
| Forward Price Earnings | 30.1205 | |
| Non Currrent Assets Other | 5.7 M | |
| Stock Based Compensation | 131.5 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Guardian Pharmacy Services. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Will Consumer Staples Distribution & Retail sector continue expanding? Could Guardian diversify its offerings? Factors like these will boost the valuation of Guardian Pharmacy. Market participants price Guardian higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Guardian Pharmacy data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.68 | Revenue Per Share | Quarterly Revenue Growth 0.2 | Return On Assets | Return On Equity |
Understanding Guardian Pharmacy requires distinguishing between market price and book value, where the latter reflects Guardian's accounting equity. The concept of intrinsic value - what Guardian Pharmacy's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Guardian Pharmacy's price substantially above or below its fundamental value.
Please note, there is a significant difference between Guardian Pharmacy's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardian Pharmacy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Guardian Pharmacy's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.